The Impact of Alemtuzumab and Basiliximab Induction on Patient Survival and Time to Bronchiolitis Obliterans Syndrome in Double Lung Transplantation Recipients

Y. Furuya, S. N. Jayarajan, S. Taghavi, F. C. Cordova, N. Patel, Akira Shiose, E. Leotta, G. J. Criner, T. S. Guy, G. H. Wheatley, L. R. Kaiser, Y. Toyoda

研究成果: ジャーナルへの寄稿記事

13 引用 (Scopus)

抄録

We examined the effect of alemtuzumab and basiliximab induction therapy on patient survival and freedom from bronchiolitis obliterans syndrome (BOS) in double lung transplantation. The United Network for Organ Sharing database was reviewed for adult double lung transplant recipients from 2006 to 2013. The primary outcome was risk-adjusted all-cause mortality. Secondary outcomes included time to BOS. There were 6117 patients were identified, of whom 738 received alemtuzumab, 2804 received basiliximab, and 2575 received no induction. Alemtuzumab recipients had higher lung allocation scores compared with basiliximab and no-induction recipients (41.4 versus 37.9 versus 40.7, p < 0.001) and were more likely to require mechanical ventilation before to transplantation (21.7% versus 6.5% versus 6.2%, p < 0.001). Median survival was longer for alemtuzumab and basiliximab recipients compared with patients who received no induction (2321 versus 2352 versus 1967 days, p = 0.001). Alemtuzumab (hazard ratio 0.80, 95% confidence interval 0.67–0.95, p = 0.009) and basiliximab induction (0.88, 0.80–0.98, p = 0.015) were independently associated with survival on multivariate analysis. At 5 years, alemtuzumab recipients had a lower incidence of BOS (22.7% versus 55.4 versus 55.9%), and its use was independently associated with lower risk of developing BOS on multivariate analysis. While both induction therapies were associated with improved survival, patients who received alemtuzumab had greater median freedom from BOS.

元の言語英語
ページ(範囲)2334-2341
ページ数8
ジャーナルAmerican Journal of Transplantation
16
発行部数8
DOI
出版物ステータス出版済み - 8 1 2016
外部発表Yes

Fingerprint

Bronchiolitis Obliterans
Lung Transplantation
Survival
Multivariate Analysis
Lung
basiliximab
alemtuzumab
Artificial Respiration
Transplantation
Databases
Confidence Intervals
Mortality
Incidence
Therapeutics

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Transplantation
  • Pharmacology (medical)

これを引用

The Impact of Alemtuzumab and Basiliximab Induction on Patient Survival and Time to Bronchiolitis Obliterans Syndrome in Double Lung Transplantation Recipients. / Furuya, Y.; Jayarajan, S. N.; Taghavi, S.; Cordova, F. C.; Patel, N.; Shiose, Akira; Leotta, E.; Criner, G. J.; Guy, T. S.; Wheatley, G. H.; Kaiser, L. R.; Toyoda, Y.

:: American Journal of Transplantation, 巻 16, 番号 8, 01.08.2016, p. 2334-2341.

研究成果: ジャーナルへの寄稿記事

Furuya, Y, Jayarajan, SN, Taghavi, S, Cordova, FC, Patel, N, Shiose, A, Leotta, E, Criner, GJ, Guy, TS, Wheatley, GH, Kaiser, LR & Toyoda, Y 2016, 'The Impact of Alemtuzumab and Basiliximab Induction on Patient Survival and Time to Bronchiolitis Obliterans Syndrome in Double Lung Transplantation Recipients', American Journal of Transplantation, 巻. 16, 番号 8, pp. 2334-2341. https://doi.org/10.1111/ajt.13739
Furuya, Y. ; Jayarajan, S. N. ; Taghavi, S. ; Cordova, F. C. ; Patel, N. ; Shiose, Akira ; Leotta, E. ; Criner, G. J. ; Guy, T. S. ; Wheatley, G. H. ; Kaiser, L. R. ; Toyoda, Y. / The Impact of Alemtuzumab and Basiliximab Induction on Patient Survival and Time to Bronchiolitis Obliterans Syndrome in Double Lung Transplantation Recipients. :: American Journal of Transplantation. 2016 ; 巻 16, 番号 8. pp. 2334-2341.
@article{97a81dd5295c47d59c5694a355a017cf,
title = "The Impact of Alemtuzumab and Basiliximab Induction on Patient Survival and Time to Bronchiolitis Obliterans Syndrome in Double Lung Transplantation Recipients",
abstract = "We examined the effect of alemtuzumab and basiliximab induction therapy on patient survival and freedom from bronchiolitis obliterans syndrome (BOS) in double lung transplantation. The United Network for Organ Sharing database was reviewed for adult double lung transplant recipients from 2006 to 2013. The primary outcome was risk-adjusted all-cause mortality. Secondary outcomes included time to BOS. There were 6117 patients were identified, of whom 738 received alemtuzumab, 2804 received basiliximab, and 2575 received no induction. Alemtuzumab recipients had higher lung allocation scores compared with basiliximab and no-induction recipients (41.4 versus 37.9 versus 40.7, p < 0.001) and were more likely to require mechanical ventilation before to transplantation (21.7{\%} versus 6.5{\%} versus 6.2{\%}, p < 0.001). Median survival was longer for alemtuzumab and basiliximab recipients compared with patients who received no induction (2321 versus 2352 versus 1967 days, p = 0.001). Alemtuzumab (hazard ratio 0.80, 95{\%} confidence interval 0.67–0.95, p = 0.009) and basiliximab induction (0.88, 0.80–0.98, p = 0.015) were independently associated with survival on multivariate analysis. At 5 years, alemtuzumab recipients had a lower incidence of BOS (22.7{\%} versus 55.4 versus 55.9{\%}), and its use was independently associated with lower risk of developing BOS on multivariate analysis. While both induction therapies were associated with improved survival, patients who received alemtuzumab had greater median freedom from BOS.",
author = "Y. Furuya and Jayarajan, {S. N.} and S. Taghavi and Cordova, {F. C.} and N. Patel and Akira Shiose and E. Leotta and Criner, {G. J.} and Guy, {T. S.} and Wheatley, {G. H.} and Kaiser, {L. R.} and Y. Toyoda",
year = "2016",
month = "8",
day = "1",
doi = "10.1111/ajt.13739",
language = "English",
volume = "16",
pages = "2334--2341",
journal = "American Journal of Transplantation",
issn = "1600-6135",
publisher = "Wiley-Blackwell",
number = "8",

}

TY - JOUR

T1 - The Impact of Alemtuzumab and Basiliximab Induction on Patient Survival and Time to Bronchiolitis Obliterans Syndrome in Double Lung Transplantation Recipients

AU - Furuya, Y.

AU - Jayarajan, S. N.

AU - Taghavi, S.

AU - Cordova, F. C.

AU - Patel, N.

AU - Shiose, Akira

AU - Leotta, E.

AU - Criner, G. J.

AU - Guy, T. S.

AU - Wheatley, G. H.

AU - Kaiser, L. R.

AU - Toyoda, Y.

PY - 2016/8/1

Y1 - 2016/8/1

N2 - We examined the effect of alemtuzumab and basiliximab induction therapy on patient survival and freedom from bronchiolitis obliterans syndrome (BOS) in double lung transplantation. The United Network for Organ Sharing database was reviewed for adult double lung transplant recipients from 2006 to 2013. The primary outcome was risk-adjusted all-cause mortality. Secondary outcomes included time to BOS. There were 6117 patients were identified, of whom 738 received alemtuzumab, 2804 received basiliximab, and 2575 received no induction. Alemtuzumab recipients had higher lung allocation scores compared with basiliximab and no-induction recipients (41.4 versus 37.9 versus 40.7, p < 0.001) and were more likely to require mechanical ventilation before to transplantation (21.7% versus 6.5% versus 6.2%, p < 0.001). Median survival was longer for alemtuzumab and basiliximab recipients compared with patients who received no induction (2321 versus 2352 versus 1967 days, p = 0.001). Alemtuzumab (hazard ratio 0.80, 95% confidence interval 0.67–0.95, p = 0.009) and basiliximab induction (0.88, 0.80–0.98, p = 0.015) were independently associated with survival on multivariate analysis. At 5 years, alemtuzumab recipients had a lower incidence of BOS (22.7% versus 55.4 versus 55.9%), and its use was independently associated with lower risk of developing BOS on multivariate analysis. While both induction therapies were associated with improved survival, patients who received alemtuzumab had greater median freedom from BOS.

AB - We examined the effect of alemtuzumab and basiliximab induction therapy on patient survival and freedom from bronchiolitis obliterans syndrome (BOS) in double lung transplantation. The United Network for Organ Sharing database was reviewed for adult double lung transplant recipients from 2006 to 2013. The primary outcome was risk-adjusted all-cause mortality. Secondary outcomes included time to BOS. There were 6117 patients were identified, of whom 738 received alemtuzumab, 2804 received basiliximab, and 2575 received no induction. Alemtuzumab recipients had higher lung allocation scores compared with basiliximab and no-induction recipients (41.4 versus 37.9 versus 40.7, p < 0.001) and were more likely to require mechanical ventilation before to transplantation (21.7% versus 6.5% versus 6.2%, p < 0.001). Median survival was longer for alemtuzumab and basiliximab recipients compared with patients who received no induction (2321 versus 2352 versus 1967 days, p = 0.001). Alemtuzumab (hazard ratio 0.80, 95% confidence interval 0.67–0.95, p = 0.009) and basiliximab induction (0.88, 0.80–0.98, p = 0.015) were independently associated with survival on multivariate analysis. At 5 years, alemtuzumab recipients had a lower incidence of BOS (22.7% versus 55.4 versus 55.9%), and its use was independently associated with lower risk of developing BOS on multivariate analysis. While both induction therapies were associated with improved survival, patients who received alemtuzumab had greater median freedom from BOS.

UR - http://www.scopus.com/inward/record.url?scp=84978880222&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978880222&partnerID=8YFLogxK

U2 - 10.1111/ajt.13739

DO - 10.1111/ajt.13739

M3 - Article

VL - 16

SP - 2334

EP - 2341

JO - American Journal of Transplantation

JF - American Journal of Transplantation

SN - 1600-6135

IS - 8

ER -